Engflag

Cinitaprida Cinfa

Quick links to important sections

Cinitaprida Cinfa

There is no image.

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cinitaprida Cinfa

What is Cinitaprida Cinfa?

Cinitaprida Cinfa is an oral gastrointestinal medication containing the active substance cinitapride. It belongs to a class of drugs known as prokinetics, which are used to improve and coordinate the movement of the digestive system.

Therapeutic Class and Mechanism

As a prokinetic agent, cinitapride acts primarily as a selective 5-HT4 receptor agonist and a 5-HT2 receptor antagonist. This mechanism stimulates the release of acetylcholine in the gastrointestinal tract, leading to increased muscle contractions and accelerated transit. Unlike some older prokinetics, it is designed to work more specifically on the upper digestive tract.

Primary Indications

This medication is primarily used to treat functional gastrointestinal disorders where motility is impaired. Its clinical applications include:

  • Gastroesophageal Reflux Disease (GERD): It is used as an adjunctive treatment for patients who do not respond sufficiently to proton pump inhibitors alone, helping to prevent the backflow of gastric acid into the esophagus.
  • Functional Dyspepsia: It helps alleviate symptoms associated with slow gastric emptying, such as early satiety, bloating, and post-meal heaviness.
  • Motility Disorders: It is indicated for the management of mild-to-moderate gastrointestinal hypomotility, facilitating the movement of food through the stomach and intestines.

Product Characteristics

Cinitaprida Cinfa is typically presented in tablet form. It is intended for use in adult populations experiencing chronic or recurrent digestive discomfort caused by delayed gastric emptying or esophageal reflux issues. By enhancing the natural rhythm of the digestive muscles, the medication aims to restore normal gastrointestinal function and reduce discomfort associated with digestive delays.

Regulatory References

  1. AEMPS Technical File (Cinitapride)

What side effects are possible with Cinitaprida Cinfa?

Possible side effects and safety information

The safety profile of Cinitapride, as detailed in official regulatory documents, is based on the classification of adverse reactions by frequency and the physiological systems affected. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Adverse effects considered common (occurring in 1% to 10% of patients) are associated with the nervous system and include somnolence and dizziness.

Effects classified as uncommon (occurring in 0.1% to 1% of patients) include fatigue from the general disorders class, headache from the nervous system, and diarrhea and dry mouth from the gastrointestinal system.

Serious Safety Considerations

The use of Cinitapride, like other benzamide derivatives, carries a risk of serious reactions related to its action as a dopamine D2 receptor antagonist, though the specific incidence is often not known.

These considerations include the potential for Extrapyramidal symptoms (EPS), which are disorders of involuntary movement. The regulatory documentation notes that the risk of developing these symptoms may be higher with long-term use of the medication. The extremely rare, life-threatening condition known as Neuroleptic Malignant Syndrome (NMS) is recognized as a theoretical risk associated with this pharmacological class.

Population-Specific Safety Notes

Official regulatory documents specify that older adults (the elderly) are explicitly documented as having an increased susceptibility to the development of Extrapyramidal symptoms. Safety precautions are also advised for individuals with severe renal impairment or severe hepatic impairment.

Safety-Related Restrictions

Due to its mechanism of promoting gastrointestinal motility, the medication is officially contraindicated in any condition where stimulating movement could be harmful, such as the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation of the digestive tract.

Overdose and Emergency Response

The official regulatory profile for Cinitaprida Cinfa overdose describes the potential clinical consequences arising from excessive exposure, focusing strictly on central nervous system and motor effects.

Clinical Manifestations of Overdose

Overdose may present with documented clinical signs, including symptoms of central nervous system disruption and motor dysfunction. Officially listed manifestations include drowsiness, disorientation, and specific extrapyramidal reactions. These motor effects are described as involuntary movements, such as muscle spasms that may affect the face, neck, and tongue.

Mandated Emergency Actions

The official guidance states that the primary immediate action required is the discontinuation of Cinitaprida Cinfa treatment. The documented overdose reactions normally resolve when the medication is stopped. Urgent medical attention must be sought if the neurological or extrapyramidal symptoms persist after the drug has been discontinued, as this warrants further medical intervention.

Supportive Management

If manifestations are persistent or in cases of excessive overdosage, specific procedures are officially described. These include gastric lavage and the administration of symptomatic medication intended to manage the lingering manifestations. It is officially stated in regulatory documents that no specific antidote is known for Cinitapride overdose; therefore, management remains supportive and procedural.

Therapeutic Uses of Cinitaprida Cinfa

Cinitaprida Cinfa is indicated for the management of symptoms related to certain gastrointestinal motility disorders. These are conditions where the normal movement of the digestive tract is disrupted, potentially leading to patient discomfort.

The medication is primarily used to offer support for individuals experiencing two main conditions: the relief of symptoms associated with Gastroesophageal Reflux Disease (GERD) and the management of discomfort linked to functional dyspepsia.

Specific symptoms that Cinitaprida Cinfa may help address include heartburn, the backward flow of stomach contents, the feeling of excessive fullness after meals (postprandial fullness), and bloating. For patients with GERD, the medication may be prescribed to enhance the effect of proton pump inhibitors for improved symptom control.

Relief for Postprandial Fullness

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cinitaprida Cinfa

This section outlines the population eligibility rules for Cinitaprida Cinfa as documented in official regulatory sources.

Contraindicated Populations (Absolute Prohibition) Use of this medicine is formally prohibited for patients with:

  • Known hypersensitivity to Cinitapride or other benzamide derivatives.
  • Conditions where increased gastrointestinal motility is harmful, such as gastrointestinal hemorrhage, obstruction, or perforation.
  • Established tardive dyskinesia induced by neuroleptics.
  • Certain neurological conditions including Pheochromocytoma, Epilepsy, Parkinson’s disease, and Prolactinoma.
Age and Physiological Restrictions Population Group Eligibility Status
Adults Eligible population for standard use.
Children/Adolescents (Under 18) Not recommended; safety and effectiveness are not established.
Older Adults (Geriatric) Use requires caution due to a potential increased risk of movement disorders.
Pregnancy/Lactation Not recommended; use should be avoided as a precautionary measure due to a lack of complete safety data.

Condition-Specific Considerations Caution is advised for patients with impaired liver or kidney function, and regular monitoring may be required. The medicine is also not recommended for patients with pre-existing stomach ulcers.

What should I know about interactions with other medicines?

Cinitaprida Cinfa Interactions with Other Medicines and Products

The officially documented interaction profile for Cinitapride is defined by three primary mechanisms: metabolic interference, its influence on gastrointestinal motility, and additive pharmacodynamic effects on the central nervous system.

Interaction Type Interacting Substance / Category Official Description of Interaction
Pharmacokinetic (Metabolism) CYP3A4 Inhibitors Cinitapride is metabolized mainly by the CYP3A4 enzyme and, to a lesser extent, CYP2C8. Co-administration with medicines that significantly inhibit CYP3A4 may alter Cinitapride exposure. For example, the strong inhibitor Ketoconazole has been documented to increase Cinitapride AUC approximately twofold.
Pharmacokinetic (Absorption) Digoxin Cinitapride may decrease the effect of Digoxin. This is due to Cinitapride's action of accelerating gastric emptying, which can result in the reduced absorption of Digoxin.
Pharmacodynamic (CNS Effects) Phenothiazines and Other Dopamine Antagonists Cinitapride enhances the effects of these dopamine antagonists on the Central Nervous System.

Substance and Constraint Notes

  • CNS Depressants: Co-administration with substances that depress the CNS, such as Alcohol, tranquillisers, hypnotics, or narcotics, will lead to the enhancement of their sedative effects.
  • Reduced Efficacy: The beneficial gastrointestinal actions of Cinitapride may be reduced by the co-administration of anticholinergic drugs and opioid analgesics.
  • Timing Rules: Official regulatory documents do not specify any mandatory separation of dose timing. No specific combination is formally classified as contraindicated in the official documents.

Mechanism of Action

Cinitapride is a substituted benzamide that functions as a mixed serotonin receptor agonist and antagonist, concurrently targeting dopaminergic receptors. Its primary biological targets are localized within the enteric nervous system of the gastrointestinal tract.

Molecular Interactions and Pathways

Cinitapride acts as an agonist at the 5-HT1 and 5-HT4 serotonergic receptors. Activation of 5-HT4 receptors, which are Gs-coupled, triggers an intracellular cascade leading to increased adenylyl cyclase activity and subsequent elevation of cyclic AMP (cAMP). This pathway facilitates the release of the excitatory neurotransmitter acetylcholine (ACh) from myenteric motor neurons.

Simultaneously, Cinitapride functions as an antagonist at the 5-HT2 serotonergic and D2 dopaminergic receptors. D2 receptor antagonism disinhibits cholinergic signaling, further promoting ACh release. The net effect of this multifactorial modulation is a systemic increase in the concentration and action of ACh within the myenteric plexus.

Downstream Consequences

The enhanced cholinergic signaling leads to the excitation of smooth muscle cells in the gastrointestinal tract, causing an increase in the frequency and amplitude of peristaltic contractions. This system-level physiological consequence modulates the gastrointestinal transit time and enhances the tone of the lower esophageal sphincter.

Dosage and Administration Information

How to Use Cinitaprida Cinfa

Cinitaprida Cinfa is an oral medication with specific usage instructions. These administration guidelines determine the standard adult dosage, frequency, and specific timing relative to meals.

Administration Guidelines

Administration Scope Detail
Route of administration The medication is designed for the oral route as a tablet.
Standard Dosing Schedule The standard regimen for adults is 1 mg per dose.
Frequency The medicine is taken three times a day (TID).
Maximum Daily Dose The advised maximum total daily intake is 3 mg.
Timing in relation to meals Each dose must be taken 15 minutes before a main meal (e.g., breakfast, lunch, and dinner).
Special Procedural Conditions The recommended dose should not be increased, as it is not associated with enhanced effect.

Population-Specific Usage Rules

Specific usage constraints apply to certain patient groups:

  • Children and Adolescents: Administration is not advisable for individuals under the age of 20, due to a lack of sufficient clinical experience in these populations.
  • Older Adults (the elderly): The standard regimen should be initiated with caution in older patients.

This structured protocol defines the appropriate procedural steps for using the medicine: the 1 mg tablet is taken orally, three times daily, specifically synchronized with mealtimes to ensure adherence to the recommended standard.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cinitaprida Cinfa

Evidence for use in Gastroesophageal Reflux Disease (GERD)

Research evaluated this compound in people with Gastroesophageal Reflux Disease (GERD), a condition characterized by fluctuating or episodic manifestations where stomach acid backs up into the esophagus. Studies examining patient-reported experiences for this indication often included randomized controlled trials (RCTs).

These studies explored outcomes related to physical discomfort, such as measured changes in symptoms associated with acid backflow, over short-term periods. Findings describe patterns observed in the studies; research provides insight into short-term changes. Data show patterns related to outcomes reflecting daily functioning or activity level, though certainty remains low and evidence is limited, as follow-up durations were limited. What remains uncertain is the full profile of this compound when used over long periods.

Evidence for use in Functional Dyspepsia (Indigestion)

This compound was studied for its use in patients diagnosed with functional dyspepsia, a condition marked by functional limitations and chronic symptoms. Research has explored short-term symptom changes primarily through trials assessing episodic symptom patterns.

Studies monitored patient-reported outcomes describing perceived discomfort. Findings indicate that some trials described patterns where the measured outcomes differed during periods of increased symptom activity. Research highlights changes measured during the study period, helping contextualize how patients reported their experience. However, the evidence quality varies across studies, and long-term effects are not well characterized.

Long-term Studies and Follow-up

Long-term effects are not well characterized for this compound, as follow-up durations were limited in most available evidence. There is limited information for long-term outcomes regarding the sustained stability of symptoms. Reported outcomes were short-term and limited to a few weeks, with limited data covering many months or years. Certainty remains low regarding the profile of this compound when used over extended timeframes.

What is Still Uncertain about Cinitaprida Cinfa

Evidence quality varies across studies, and findings were mixed on certain outcome measures, contributing to low certainty. Major uncertainties include the lack of information for long-term outcomes and the scarcity of comparative evidence. The current evidence helps contextualize how patients reported their experience but does not provide individual predictions, and more research is needed to fully characterize the compound's place within the broader evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Cinitaprida Cinfa (FAQ)

Q: Is Cinitaprida Cinfa used for general stomach pain?

Official regulatory information indicates that this medicine is used to manage gastrointestinal motility disorders. Its primary action is to improve the muscular movement and transit within the digestive system. It is not listed as a medication for general pain relief.

Q: How does Cinitaprida Cinfa differ from other motility-boosting drugs?

Cinitaprida is characterized by its specific dual mechanism of action. According to official sources, it functions as both a stimulator (5-HT4 receptor agonist) and a blocker (Dopamine D2 receptor antagonist) in the gut. This mechanism of action is its defining pharmacological characteristic.

Q: Does Cinitaprida Cinfa affect sleep or cause insomnia?

Adverse effects on the nervous system are documented in official safety information, including somnolence (drowsiness) and dizziness. These effects may affect alertness. However, insomnia (difficulty sleeping) is not explicitly listed among the common or uncommon side effects.

Q: Does Cinitaprida Cinfa interact with anxiety or depression medicines?

Regulatory warnings state that using this medicine alongside substances that depress the Central Nervous System (CNS), such as certain tranquillisers, can enhance their sedative effects. Additionally, some antidepressants may alter how Cinitapride is processed by the body, potentially changing its exposure.

Q: What is the typical age range of patients prescribed Cinitaprida Cinfa?

The medicine is generally intended for use by adults. Official documents state that administration is not advisable for individuals under the age of 20 due to limited clinical experience. The regulatory label also advises that the standard regimen should be initiated with caution in older adults.

Q: Are there specific foods or drinks that should be avoided while taking Cinitaprida Cinfa?

Official interaction guidance specifies that alcohol consumption should be avoided, as it can enhance the medicine's sedative effects. No specific food restrictions have been officially established or listed in regulatory documents.

Q: Can Cinitaprida Cinfa affect driving or operating machinery?

Regulatory documents state that caution is required and advise against driving or operating machinery because the medicine may cause somnolence (drowsiness) and dizziness. Individuals should assess their personal alertness when using this medicine.

Q: Is Cinitaprida Cinfa generally well-tolerated?

Official safety profiles indicate that the most commonly reported adverse effects, such as somnolence and dizziness, are associated with the nervous system. They are classified as common adverse reactions.

Q: Is Cinitaprida Cinfa similar to metoclopramide or domperidone?

Yes, Cinitapride is similar in that it belongs to the benzamide derivative chemical class. It also shares the mechanism of blocking the Dopamine D2 receptor with these other medicines.

Q: How long does it typically take for Cinitaprida Cinfa to start working?

According to pharmacokinetic data, the maximum concentration of the active substance in the blood is typically measured within about two hours after oral administration.

Q: What is the expected duration of treatment with Cinitaprida Cinfa?

The total duration of treatment is guided by professional clinical oversight. However, clinical trials frequently evaluate the efficacy and safety of the compound over a 4-week treatment period.

Q: What heart conditions require caution when using Cinitaprida Cinfa?

Official warnings state that caution is advised for patients with a history of heart rhythm disorders. Additionally, reports of palpitations or an irregular heartbeat are recognized as potential adverse effects.

Q: What should be done if a dose of Cinitaprida Cinfa is missed?

If a dose is missed, patient information describes the standard procedure as taking the missed dose as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped. Regulatory guidance states that a double dose should not be taken to make up for a missed dose.

Q: What is the official recommended duration for Cinitaprida Cinfa use?

The total duration of treatment is guided by professional clinical oversight. However, clinical trials frequently evaluate the efficacy and safety of the compound over a 4-week treatment period.

Q: Where is Cinitaprida Cinfa approved for use (e.g., in which countries)?

Cinitaprida Cinfa is approved and available in several countries worldwide. Regulatory data and product labels are primarily associated with nations across Europe and parts of Asia.

Q: Is Cinitaprida Cinfa approved by the FDA in the United States?

Official records show that Cinitaprida Cinfa is generally not listed among the medicines approved by the U.S. Food and Drug Administration (FDA) for sale in the United States.

Q: Are there ongoing clinical trials or new research areas for Cinitaprida Cinfa?

Information regarding new or ongoing research, studies, and clinical trials for Cinitaprida is available to the public. This data can be found by consulting official government-maintained clinical trial registries.

Q: Does Cinitaprida Cinfa have a risk of drug dependence?

Official regulatory safety information indicates that no habit-forming tendency or risk of drug dependence has been reported for Cinitapride.

Q: What are the possible signs of an overdose with Cinitaprida Cinfa?

Overdose symptoms typically involve signs of Central Nervous System (CNS) effects. These can include excessive drowsiness, confusion, and the appearance of extrapyramidal symptoms (involuntary movement disorders).

Q: Does Cinitaprida Cinfa affect hormone levels?

The medicine's mechanism as a D2 dopamine receptor antagonist means it may influence prolactin levels. This is why official contraindications list conditions like Prolactinoma (a condition involving excess prolactin).

Q: Can Cinitaprida Cinfa cause skin rash or itching?

Official safety information recognizes that signs of an allergic reaction, such as skin rash, itching, or swelling, are potential adverse effects. These types of reactions are generally considered rare.

Q: Does Cinitaprida Cinfa interact with grapefruit?

The drug is mainly broken down in the body by the CYP3A4 enzyme. Regulatory interaction warnings advise caution when combining it with known strong CYP3A4 inhibitors, as this may increase the medicine's exposure in the body.

How should Cinitaprida Cinfa be stored and disposed of?

How to Store and Dispose of Cinitaprida Cinfa?

The storage and disposal of Cinitaprida Cinfa must strictly adhere to the conditions documented in official regulatory labeling to ensure product integrity and environmental safety.

Storage Requirements

  • Temperature: Store the tablets at a temperature below 30 C.
  • Handling: The medication must be protected from excessive heat and moisture and kept in its original pack (blister).
  • Security: It is a mandatory requirement to keep this medicine out of the sight and reach of children.
  • Stability: Do not use the medication after the expiration date printed on the packaging.

Disposal Instructions

Expired or unused Cinitaprida Cinfa must not be disposed of through wastewater or with household waste. The packaging and unused product should be taken to a designated pharmacy collection point for proper handling, in compliance with environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cinitaprida Cinfa found in:

A-Z Index: